• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Springworks Therapeutics Inc (NQ: SWTX )

    30.62 +0.49 (+1.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 481,117
    Open 30.11
    Bid (Size) 29.73 (1)
    Ask (Size) 31.20 (2)
    Prev. Close 30.13
    Today's Range 29.73 - 30.68
    52wk Range 18.00 - 53.92
    Shares Outstanding 49,127,913
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -16.11%
    -16.11%
    1 Month
    -6.73%
    -6.73%
    3 Month
    -8.41%
    -8.41%
    6 Month
    -32.12%
    -32.12%
    1 Year
    +21.27%
    +21.27%

    More News

    Read More
    SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
    Via Investor's Business Daily
    SWTX Stock Earnings: SpringWorks Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    SpringWorks Therapeutics: Q4 Earnings Insights
    Via Benzinga
    SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    7 Biotech Stocks to Buy as Sector Rotation Ramps Up
    Via InvestorPlace
    SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Present at Upcoming Investor Conferences
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From SpringWorks Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.